F-star Therapeutics, Inc. Common Stock
FSTX
FSTX was delisted on the 8th of March, 2023.
54 hedge funds and large institutions have $74M invested in F-star Therapeutics, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 4 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 13
1% more capital invested
Capital invested by funds: $73.5M → $74M (+$530K)
5% less funds holding
Funds holding: 57 → 54 (-3)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$263K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$130K |
| 3 |
BlackRock
New York
|
+$101K |
| 4 |
Renaissance Technologies
New York
|
+$67.4K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$62.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$596K |
| 2 |
MAM
Morse Asset Management
Darien,
Connecticut
|
-$206K |
| 3 |
Morgan Stanley
New York
|
-$205K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$58K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$50.6K |
FSTX Hedge Fund Activity: Q1 2019 in Review
54 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q1 2019, worth a combined $74M — up 0.72% from $73.5M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of FSTX and 1 opened new positions — a net loss of 3 holders — while 13 trimmed existing stakes and 16 added.
The largest buyer was Sectoral Asset Management, adding an estimated $263K. The largest seller was International Biotechnology Trust, exiting entirely with an estimated $596K sold.
- 54 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q1 2019, down from 57 in Q4 2018.
- Funds reported $74M of F-star Therapeutics, Inc. Common Stock stock for Q1 2019, up 0.72% quarter-over-quarter.
- 1 fund opened new F-star Therapeutics, Inc. Common Stock positions in Q1 2019 and 4 closed out, a net change of -3 holders.
- The largest F-star Therapeutics, Inc. Common Stock buyer in Q1 2019 was Sectoral Asset Management, an estimated $263K added.
- The largest F-star Therapeutics, Inc. Common Stock seller in Q1 2019 was International Biotechnology Trust, an estimated $596K sold.
Based on aggregated 13F filings for Q1 2019.